Acadian Asset Management
KNTE

Acadian Asset Management’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Acadian Asset Management’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-964,881
Closed -$2.56M – 1946
2024
Q1 		$2.56M Buy
964,881
+134,388
+16% +$333K 0.01% 604
2023
Q4 		$1.97M Buy
830,493
+93,807
+13% +$166K 0.01% 676
2023
Q3 		$1.03M Buy
736,686
+305,884
+71% +$735K ﹤0.01% 847
2023
Q2 		$1.3M Buy
430,802
+401,887
+1,390% +$1.55M 0.01% 817
2023
Q1 		$179K Buy
28,915
+17,929
+163% +$109K ﹤0.01% 1278
2022
Q4 		$67K Buy
10,986
+2,830
+35% +$23K ﹤0.01% 1516
2022
Q3 		$97K Sell
8,156
-2,610
-24% -$34.2K ﹤0.01% 1374
2022
Q2 		$136K Buy
+10,766
New +$100K ﹤0.01% 1290

Acadian Asset Management's KNTE Position: Q2 2024 in Review

Acadian Asset Management sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2024, closing a stake of 964,881 shares — an estimated $2.56M sold.

Acadian Asset Management first reported a position in KNTE in Q2 2022 and held it in 8 quarters. The position peaked at $2.56M in Q1 2024. 0 funds tracked by Wall St. Rank hold KNTE as of Q2 2024.

  • Acadian Asset Management reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Acadian Asset Management sold 964,881 Kinnate Biopharma Inc. Common Stock shares in Q2 2024, an estimated $2.56M.
  • Acadian Asset Management first reported a position in Kinnate Biopharma Inc. Common Stock in Q2 2022 and held it in 8 quarters.
  • Acadian Asset Management's Kinnate Biopharma Inc. Common Stock position peaked at $2.56M in Q1 2024.
  • 0 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2024.

Based on Acadian Asset Management's 13F filing for Q2 2024, filed 6 Aug 2024.